Barely Significant
← all excerpts

Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma.

Cancer Manag Res · 2011 · PMC3173017 · PMID 21931501

Europe PMCDOI
3
hedged sentences
0.0500
closest p · 1.0× alpha
0.0500
boldest claim

The sentences

nominally significantP ≤ 0.05actually significant
Polymorphisms in IL-8, HIF1A, NR1l2, and VEGFA showed nominally significant association ( P ≤ 0.05) with PFS when compared with the wild-type genotypes.

also in 7,732 other papers

highly significantno p-value reported
Conclusion: role of pazopanib in RCC therapy In the Phase III randomized double-blind placebo-controlled trial, pazopanib treatment produced a highly significant PFS improvement for either treatment-naïve or cytokine pretreated patients.

also in 132,142 other papers

a favorable trendno p-value reported
The survival data suggest a favorable trend associated with pazopanib treatment, in spite of significant crossover by subjects in the placebo arm.

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.